GLP Watchdog

GoodRx vs Hims

Hims has an open FDA warning letter dated September 9, 2025. GoodRx has none. No price lines up like for like. They share brand-name tirzepatide pen, but Hims' $299 covers the medication only, with a separate membership on top.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / Hims

GoodRx logo

GoodRx

7.8/10

Hims logo

Hims

6.7/10

FDA warning letters
None on record
Pharmacy
Brand-name only; no compounding
Lowest standing price
$149/moFoundayo (orforglipron) pill
$149/moBrand-name semaglutide pill, medication only, membership extra
States
48 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit GoodRx
Visit Hims

Neither GoodRx nor Hims pays us. Links to them earn nothing. Scores: GoodRx 7.8, Hims 6.7. How we are paid

What the record shows

  1. 01

    Hims has an open FDA warning letter dated September 9, 2025. GoodRx has none.

  2. 02

    No price lines up like for like. They share brand-name tirzepatide pen, but Hims' $299 covers the medication only, with a separate membership on top.

  3. 03

    Only Hims lists a price for brand-name semaglutide pen and brand-name semaglutide pill.

  4. 04

    Hims covers two states GoodRx does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

Hims

Brand-name tirzepatide pen

$299/mo

$3,588 a year

$299/mo

medication only, membership extra; not compared

Foundayo (orforglipron) pill

$149/mo

$1,788 a year

$149/mo

medication only, membership extra; not compared

Brand-name semaglutide pen
Not sold or not priced

$199/mo

medication only, membership extra; not compared

Brand-name semaglutide pill
Not sold or not priced

$149/mo

medication only, membership extra; not compared

Price includes
Not stated
Medication
Billed separately
Not stated
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
Monthly membership, auto-renews
Refunds
Services and medication are generally non-refundable
First month's membership fee is non-refundable; partial-period refunds are not guaranteed
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. GoodRx: October 30, 2026. Hims: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • No FDA warning letter on record
Visit GoodRx

The case for Hims

6.7/10
  • Sells brand-name semaglutide pen and brand-name semaglutide pill, which GoodRx does not price
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
  • Lowest price covers the medication only, with a separate membership on top
Visit Hims

Scores

GoodRx 7.8 · Hims 6.7 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

5.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
6.0

Accessibility10%

9.7A
vs
B
10.0

Support10%

5.0A
vs
B
3.0

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs Hims: questions

Hims has an open FDA warning letter dated September 9, 2025. GoodRx has none. Letters are matched to a seller by company, domain and address, never by a similar name.
No price lines up like for like. They share brand-name tirzepatide pen, but Hims' $299 covers the medication only, with a separate membership on top. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. Hims states you can cancel at any time; refunds: first month's membership fee is non-refundable; partial-period refunds are not guaranteed.
Neither GoodRx nor Hims pays us. Links to them earn nothing. Scores: GoodRx 7.8, Hims 6.7.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks